Anoro Ellipta

Anoro Ellipta

umeclidinium + vilanterol




Zuellig Pharma
Concise Prescribing Info
Predispensed umeclidinium 62.5 mcg, vilanterol (as trifenatate) 25 mcg. Delivered dose of umeclidinium 55 mcg, vilanterol (as trifenatate) 22 mcg
Maintenance bronchodilator treatment to relieve symptoms associated w/ COPD.
Dosage/Direction for Use
Hypersensitivity. Severe milk-protein allergy.
Special Precautions
Patients w/ asthma; severe CV disease, narrow-angle glaucoma, urinary retention; convulsive disorder or thyrotoxicosis & patients unusually responsive to β2-adrenergic agonists. Discontinue if paradoxical bronchospasm occurs. Not for the treatment of acute episodes of bronchospasm. If deterioration of COPD during treatment, re-evaluate patients & COPD treatment regimen. Concomitant use w/ other medicines that may cause hypokalemia. Monitor glucose in diabetic patients. Severe hepatic impairment. Pregnancy & lactation. Childn <18 yr.
Adverse Reactions
UTI, sinusitis, nasopharyngitis, pharyngitis, upper resp tract infection; headache; cough, oropharyngeal pain; constipation, dry mouth.
Drug Interactions
Avoid concurrent use of either nonselective or selective β-adrenergic blockers. May inhibit metabolism & increase systemic exposure w/ strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, itraconazole, ritonavir, telithromycin). May potentiate adverse reactions w/ known inhaled antimuscarinics & β2-adrenergic agonist. May potentiate possible hypokalaemic effect w/ methylxanthine derivatives, steroids or non-K-sparing diuretics.
ATC Classification
R03AL03 - vilanterol and umeclidinium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.
Anoro Ellipta inhalation powd 62.5 mcg/25 mcg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in